U.S. Branded Generics Market Size & Outlook, 2021-2030
U.S. branded generics market, 2018-2030 (US$M)
Related Markets
U.S. branded generics market highlights
- The U.S. branded generics market generated a revenue of USD 40.9 billion in 2021 and is expected to reach USD 61.8 billion by 2030.
- The U.S. market is expected to grow at a CAGR of 4.7% from 2022 to 2030.
- In terms of segment, anti-hypertensive was the largest revenue generating drug class in 2021.
- Hormones is the most lucrative drug class segment registering the fastest growth during the forecast period.
Branded generics market data book summary
| Market revenue in 2021 | USD 40.9 billion |
| Market revenue in 2030 | USD 61.8 billion |
| Growth rate | 4.7% (CAGR from 2021 to 2030) |
| Largest segment | Anti-hypertensive |
| Fastest growing segment | Hormones |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD billion |
| Market segmentation | Alkylating Agents, Antimetabolites, Hormones, Anti-hypertensive, Lipid Lowering drugs, Anti-depressants, Anti-psychotics, Anti-epileptics |
| Key market players worldwide | Teva Pharmaceutical Industries Ltd, Lupin, Sanofi SA, Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, GlaxoSmithKline, Pfizer Inc, Apotex Inc., Viatris Inc |
Other key industry trends
- In terms of revenue, U.S. accounted for 17.8% of the global branded generics market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. branded generics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 7.1 billion by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Branded Generics Market Scope
Branded Generics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. branded generics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to branded generics market will help companies and investors design strategic landscapes.
Anti-hypertensive was the largest segment with a revenue share of 15.65% in 2021. Horizon Databook has segmented the U.S. branded generics market based on alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptics covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. branded generics market is anticipated to witness moderate growth over the forecast period, owing to increase in number of ANDA approvals and first-to-file benefits, such as Paragraph IV (PIV) certification. As per U.S. FDA, the number of ANDA approvals increased from 971 in 2018 to 1,171 in 2019.
In addition, 107 first generic products were approved, which may contribute to market growth due to increased profitability through 180 days of exclusivity period. There is high competition among generic manufacturers in the U.S.
According to FDA, generic competition leads to cost savings of 95% in the U.S. However, this competitive environment leads to shortage of generic medicines, as operational costs are high. The buyers in the U.S. are leveraging the strong competition between manufacturers and excess capacity in manufacturing and R&D.
Reasons to subscribe to U.S. branded generics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. branded generics market databook
-
Our clientele includes a mix of branded generics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. branded generics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. branded generics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. branded generics market size, by drug class, 2018-2030 (US$M)
U.S. Branded Generics Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
